Fusen Pharmaceutical Company Limited (1652.HK)

HKD 0.81

(-2.41%)

Market Cap (In HKD)

590.2 Million

Revenue (In HKD)

565.6 Million

Net Income (In HKD)

-36.27 Million

Avg. Volume

29.37 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.75-1.4
PE
-
EPS
-
Beta Value
0.547
ISIN
KYG370981030
CUSIP
G37098103
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Zhiming Cao
Employee Count
-
Website
https://www.fusenyy.com
Ipo Date
2018-07-11
Details
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.

More Stocks